GlaxoSmithKline scraps a LAG3 study, marking another failure for the pipeline after a critical setback
Another gap has appeared in GlaxoSmithKline’s pipeline.
Friday morning the Australian biotech Immutep put out word that Hal Barron’s R&D group at GSK had decided to scrap a Phase II proof-of-concept study in ulcerative colitis for their anti-LAG3 therapy GSK2831781. According to the biotech, the program didn’t survive an interim review.
The trial was stopped by GSK based on the assessment of clinical data as part of a planned interim analysis conducted in consultation with the trial’s Data Review Committee. GSK is conducting further reporting, assessment and analyses of the efficacy and safety data and evaluating the biology to determine next steps for the GSK2831781 development program.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,200+ biopharma pros reading Endpoints daily — and it's free.